Comment on "Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients"

被引：3
|
作者：
Ballmann, Manfred [1 ]
Prinz, Nicole [2 ]
Glass, Aenne [3 ]
Holl, Reinhard [2 ]
机构：
[1] Univ Med Pediat Clin, Ernst Heydemann Str 8, D-18057 Rostock, Germany
[2] Univ Ulm, Inst Epidemiol & Med Biometry, Albert Einstein Allee 41, D-89081 Ulm, Germany
[3] Univ Med Rostock, Inst Biostat & Informat Med & Age Res IBIMA, Ernst Heydemann Str 8, D-18057 Rostock, Germany
来源：
JOURNAL OF CYSTIC FIBROSIS | 2020年 / 19卷 / 05期
关键词：
D O I：
10.1016/j.jcf.2020.04.009
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：839 / 839
页数：1
相关论文
共 50 条
  • [1] Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients
    Misgault, Bastien
    Chatron, Eva
    Reynaud, Quitterie
    Touzet, Sandrine
    Abely, Michel
    Melly, Laurent
    Dominique, Stephane
    Troussier, Francoise
    Ronsin-Pradel, Olivia
    Gerardin, Michele
    Mankikian, Julie
    Cosson, Laure
    Chiron, Raphael
    Bounyar, Leila
    Porzio, Michel
    Durieu, Isabelle
    Weiss, Laurence
    Kessler, Romain
    Kessler, Laurence
    JOURNAL OF CYSTIC FIBROSIS, 2020, 19 (05) : 712 - 716
  • [2] Can lumacaftor-ivacaftor reverse glucose-tolerance abnormalities in cystic fibrosis?
    Kessler, Laurence
    JOURNAL OF CYSTIC FIBROSIS, 2020, 19 (04) : 666 - 666
  • [3] Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor
    Li, Angel
    Vigers, Tim
    Pyle, Laura
    Zemanick, Edith
    Nadeau, Kristen
    Sagel, Scott D.
    Chan, Christine L.
    JOURNAL OF CYSTIC FIBROSIS, 2019, 18 (01) : 144 - 149
  • [4] Adherence to lumacaftor-ivacaftor therapy in patients with cystic fibrosis in France
    Olivereau, Lucie
    Nave, Viviane
    Garcia, Stephan
    Perceval, Marie
    Rabilloud, Muriel
    Durieu, Isabelle
    Reynaud, Quitterie
    JOURNAL OF CYSTIC FIBROSIS, 2020, 19 (03) : 402 - 406
  • [5] Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy
    Connett, G. J.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 2405 - 2412
  • [6] Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis
    Burgel, Pierre-Regis
    Munck, Anne
    Durieu, Isabelle
    Chiron, Raphael
    Mely, Laurent
    Prevotat, Anne
    Murris-Espin, Marlene
    Porzio, Michele
    Abely, Michel
    Reix, Philippe
    Marguet, Christophe
    Macey, Julie
    Sermet-Gaudelus, Isabelle
    Corvol, Harriet
    Bui, Stephanie
    Lemonnier, Lydie
    Dehillotte, Clemence
    Da Silva, Jennifer
    Paillasseur, Jean-Louis
    Hubert, Dominique
    Mounard, Julie
    Poulet, Claire
    Rames, Cinthia
    Person, Christine
    Troussier, Francoise
    Urban, Thierry
    Dalphin, Marie-Laure
    Dalphin, Jean-Claude
    Pernet, Didier
    Richaud-Thiriez, Benedicte
    Fayon, Mickael
    Macey-Caro, Julie
    Campbell, Karine
    Laurans, Muriel
    Borderon, Corinne
    Heraud, Marie-Christine
    Labbe, Andre
    Montcouquiol, Sylvie
    Bassinet, Laurence
    Remus, Natascha
    Fanton, Annlyse
    Houzel-Charavel, Anne
    Huet, Frederic
    Perez-Martin, Stephanie
    Boldron-Ghaddar, Amale
    Scalbert, Manuela
    Camara, Boubou
    Llerena, Catherine
    Pin, Isabelle
    Quetant, Sebastien
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201 (02) : 188 - 197
  • [7] Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function
    Burgel, Pierre-Regis
    Durieu, Isabelle
    Chiron, Raphael
    Mely, Laurent
    Prevotat, Anne
    Murris-Espin, Marlene
    Porzio, Michele
    Abely, Michel
    Reix, Philippe
    Marguet, Christophe
    Macey, Julie
    Sermet-Gaudelus, Isabelle
    Corvol, Harriet
    Bui, Stephanie
    Biouhee, Tiphaine
    Hubert, Dominique
    Munck, Anne
    Lemonnier, Lydie
    Dehillotte, Clemence
    Da Silva, Jennifer
    Paillasseur, Jean-Louis
    Martin, Clemence
    JOURNAL OF CYSTIC FIBROSIS, 2021, 20 (02) : 220 - 227
  • [8] Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
    Rehman, Abdul
    Baloch, Noor Ul-Ain
    Janahi, Ibrahim A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (18): : 1783 - 1783
  • [9] Real World Assessment of Patients with Cystic Fibrosis Treated with Lumacaftor-Ivacaftor and Transitioned to Tezacaftor-Ivacaftor
    Christmas, A.
    O'Hagan, A. R.
    Morton, R. L.
    Eid, N. S.
    Bickel, S. G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [10] Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
    Wainwright, C. E.
    Elborn, J. S.
    Ramsey, B. W.
    Marigowda, G.
    Huang, X.
    Cipolli, M.
    Colombo, C.
    Davies, J. C.
    De Boeck, K.
    Flume, P. A.
    Konstan, M. W.
    McColley, S. A.
    Mccoy, K.
    McKone, E. F.
    Munck, A.
    Ratjen, F.
    Rowe, S. M.
    Waltz, D.
    Boyle, M. P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (03): : 220 - 231
12345